BioCentury | Oct 31, 2020
Finance

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

...and CEO Sommadossi, who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....
BioCentury | Oct 27, 2020
Finance

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

...CEO Jean-Pierre Sommadossi, who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain By Jeff...
...veteran biotech entrepreneur who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...any damage until there’s a vaccine,” Sommadossi said. Sommadossi helped found two prior antiviral companies: Idenix Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

...she was also interim CFO at Neon Therapeutics Inc. (NASDAQ:NTGN), and was previously CFO of Idenix...
BioCentury | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
Items per page:
1 - 10 of 496
BioCentury | Oct 31, 2020
Finance

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

...and CEO Sommadossi, who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....
BioCentury | Oct 27, 2020
Finance

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

...CEO Jean-Pierre Sommadossi, who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain By Jeff...
...veteran biotech entrepreneur who helped found two antiviral companies that were acquired in multibillion-dollar deals: Idenix Pharmaceuticals Inc....
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...any damage until there’s a vaccine,” Sommadossi said. Sommadossi helped found two prior antiviral companies: Idenix Pharmaceuticals Inc....
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

...she was also interim CFO at Neon Therapeutics Inc. (NASDAQ:NTGN), and was previously CFO of Idenix...
BioCentury | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011. Mayers was EVP and CMO of Idenix Pharmaceuticals Inc....
...which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014. The pharma dropped Idenix's...
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
BioCentury | Sep 29, 2017
Clinical News

Merck discontinues HCV candidates

...gained uprifosbuvir (MK-3682), a component of MK-3682B and MK-3682C, through its $3.9 billion acquisition of Idenix Pharmaceuticals Inc....
Items per page:
1 - 10 of 496